SPRINTR: Swedish PRecision medicine Initiative for Novel Treatments and Research-towards efficient recruitment to clinical trials for prostate cancer

Edsjo A, Russnes HG, Lehtio J, Tamborero D, Hovig E, Stenzinger A,

et al. High-throughput molecular assays for inclusion in personalised oncology trials – state-of-the-art and beyond. J Intern Med. 2024;295(6):785–803. DOI: https://doi.org/10.1111/joim.13785

Abdueva D, Wing M, Schaub B, Triche T, Davicioni E. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J Mol Diagn. 2010;12(4):409–17. DOI: https://doi.org/10.2353/jmoldx.2010.090155

Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, Ozguroglu M, et al. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial. Nat Med. 2025;31(12):4109–18. DOI: https://doi.org/10.1038/s41591-025-03961-8

Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. Ann Oncol. 2026;37(1):53–68. DOI: https://doi.org/10.1016/S0302-2838(26)00576-2

Josefsson A, Wikstrom P, Granfors T, Egevad L, Karlberg L, Stattin P, et al. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol. 2005;48(4):577–83. DOI: https://doi.org/10.1016/j.eururo.2005.05.016

Schlomm T, Iwers L, Kirstein P, Jessen B, Kollermann J, Minner S, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 2008;21(11):1371–8. DOI: https://doi.org/10.1038/modpathol.2008.104

Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, et al. Transcriptomic heterogeneity in high-risk prostate cancer and implications for extraprostatic disease at presentation on prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. 2023;6(2):224–7. DOI: https://doi.org/10.1016/j.euo.2023.02.009

Spyratou V, Freyhult E, Bergh A, Thellenberg-Karlsson C, Wikstrom P, Welen K, et al. Ki67 and prostate specific antigen are prognostic in metastatic hormone naive prostate cancer. Acta Oncol. 2023;62(12):1698–706. DOI: https://doi.org/10.1080/0284186X.2023.2254480

Thysell E, Kohn L, Semenas J, Jaremo H, Freyhult E, Lundholm M, et al. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C. Mol Oncol. 2022;16(4):846–59. DOI: https://doi.org/10.1002/1878-0261.13158

Thysell E, Vidman L, Ylitalo EB, Jernberg E, Crnalic S, Iglesias-Gato D, et al. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor. Mol Oncol. 2019;13(8):1763–77. DOI: https://doi.org/10.1002/1878-0261.12526

Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, et al. Clinical and genomic implications of luminal and basal subtypes across carcinomas. Clin Cancer Res. 2019;25(8):2450–7. DOI: https://doi.org/10.1158/1078-0432.CCR-18-3121

Genomic Medicine Sweden. GMS560: a broad targeted NGS gene panel for comprehensive genomic profiling of solid tumors [Internet]. 2023 [cited 2026 Mar 02]. Available from: https://genomicmedicine.se/wp-content/uploads/2023/11/GMS560_synopsis.pdf

Peng Z, Skoog L, Hellborg H, Jonstam G, Wingmo IL, Hjalm-Eriksson M, et al. An expression signature at diagnosis to estimate prostate cancer patients’ overall survival. Prostate Cancer Prostatic Dis. 2014;17(1):81–90. DOI: https://doi.org/10.1038/pcan.2013.57

Edsjo A, Friedman M, Rosenquist R. [Genomic Medicine Sweden – a national initiative for the broad introduction of precision medicine in Swedish healthcare]. Lakartidningen. 2021;118:21023.

Genomic Medicine Sweden. Genomic Medicine Sweden, GMS, is paving the way for improved diagnostics, care and treatment [Internet]. 2026 [cited 2026 Apr 12]. Available from: https://genomicmedicine.se/en/

Clinical Trials Sweden. Clinical studies Sweden – development and support of clinical studies in healthcare [Internet]. 2026 [cited 2026 Mar 15]. Available from: https://kliniskastudier.se/english

Biobank Sweden. Biobank Sweden – a national infrastructure for biobanking [Internet]. 2026 [cited 2026 Apr 12]. Available from: https://biobanksverige.se/en/a-national-infrastructure-for-biobanking/

European Commission. EUnetCCC – European network of Comprehensive Cancer Centres [Internet]. 2026 [cited 2026 Apr 12]. Available from: https://health.ec.europa.eu/non-communicable-diseases/cancer/europes-beating-cancer-plan-eu4health-financed-projects/projects/eunetccc_en